Biologicals and targeted synthetic Disease Modifying AntiRheumatic Drugs in inflammatory rheumatic diseases: observational daily clinical practice study "The Reade Rheumatology Registry"

Biologicals and targeted synthetic Disease Modifying AntiRheumatic Drugs in inflammatory rheumatic diseases: observational daily clinical practice study "The Reade Rheumatology Registry" - Biologicals and tsDMARDs: The Reade Antirheumatic Drugs Registry

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON53055

Enrollment

2000

Registered

2016-10-12

Start date

2016-12-06

Completion date

Unknown

Last updated

2026-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatic diseases Rheumatic diseases

Interventions

None listed

Eligibility

Age

16 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients with RA, PsA, AS or nrAxSpA who are treated with biologics or tsDMARDs or in whom treatment with these agents is initiated. Plus an written informed consent.

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
Efficacy will be determined in comparison to baseline by comparing disease activity, radiological progression and functional capacity during follow-up. Safety will be determined by the occurrence of side effects. Changes in (bio)markers during treatment will be analyzed versus baseline. According to the rheumatic disease, the following study parameters are involved: RA: DAS28; followed by outcome measurements like EULAR response criteria, CDAI and SDAI criteria PsA: DAS28, PASI; followed by outcome measurements like EULAR response criteria, CDAI and SDAI criteria AS/nrAxSpA: BASDAI, BASMI en daaruit volgend onder andere de ASDAS.	—

Measure

Time frame

Efficacy will be determined in comparison to baseline by comparing disease activity, radiological progression and functional capacity during follow-up. Safety will be determined by the occurrence of side effects. Changes in (bio)markers during treatment will be analyzed versus baseline. According to the rheumatic disease, the following study parameters are involved: RA: DAS28; followed by outcome measurements like EULAR response criteria, CDAI and SDAI criteria PsA: DAS28, PASI; followed by outcome measurements like EULAR response criteria, CDAI and SDAI criteria AS/nrAxSpA: BASDAI, BASMI en daaruit volgend onder andere de ASDAS.

—

Secondary

Measure	Time frame
- adverse events - Swollen and painful joints (28 joint count) - ESR en/of CRP - lipid profiles - drug levels and antibodies - radiological progression - uveitis, psoriasis, IBD, tendinitis - improvement of functionality (BASMI) for AS - improvement of functionality (RAPID-3) for RA, PsA and AS - length, weight, blood pressure - Charlson Index - VAS Global and pain - LEI index - PASI	—

Countries

Netherlands

Contacts

Public ContactR.J. Jong

Reade

research@reade.nl020-2421000

Outcome results